Cisplatin or Oxaliplatin

Phase 2Small molecule

Cisplatin or Oxaliplatin is one of 6 small molecule programs targeting Hilar Cholangiocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hilar CholangiocarcinomaNot yet recruiting

Hilar CholangiocarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Hilar Cholangiocarcinoma

#DrugCompanyPhaseTrials

Adrucil

EElorac, Inc.

Approved

—2

Photofrin

PPinnacle Biologics Inc.

Beyfortus

1 4

Gemzar

Johnson & Johnson

Phase 2

1 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Preclinical

1 6

Cisplatin or Oxaliplatin

JJinbo Yue

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Hilar Cholangiocarcinoma

NCT07030140

Clinical

Trials by Indication[1]

Hilar Cholangiocarcinoma1 trial

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Not yet recruiting·JJinbo Yue·Phase 2·NCT07030140·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cisplatin or Oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cisplatin or Oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cisplatin or Oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jinbo Yue company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJinbo Yue

Cisplatin or Oxaliplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Hilar Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News